RESEARCH STUDIES & Clinical Trials

Clinical Trial ID: NCT04396860 A Randomized Phase II/III Open-Label Study Of Ipilimumab And Nivolumab Versus Temozolomide In Patients With Newly Diagnosed MGMT (Tumor O-6- Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma

Status

Open

Description

Objective

Treatment

Conditions

Other

Phases

II/III

Therapies

Drugs

Age Group

Adult

Main Investiagtor

Cavaliere, Robert

Practice

CNS

Scope

National

Participating Institutions

Baptist MD Anderson Cancer Center

Eligibility

Nct ID Number

NCT04396860

Secondary Trial ID Number

NRG_BN007

Keywords

Treatment

More Information

clinicaltrials.gov

“The support team gave not only me but my family a sense of peace.”

—David Smith, Patient

At Baptist MD Anderson, you can rely on our cancer experts to deliver the complex, coordinated care needed to address your condition. Learn more about Patricia’s story as well as others from our patients.